SCHEMBL3555772

SCHEMBL3555772

COc1ccc2[nH]c(C)c(OCCN(C)C)c2c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 6/20 0.64
HTR1D P28221 5/20 0.64
HTR1A P08908 4/20 0.64
HTR7 P34969 4/20 0.64
HTR5A P47898 4/20 0.64
HTR1E P28566 3/20 0.64
SLC6A2 P23975 1/20 0.64
HTR2A P28223 2/20 0.54
HTR2C P28335 2/20 0.54
ALDH1A1 P00352 8/20 0.53
KDM4E B2RXH2 6/20 0.51
MAPT P10636 3/20 0.51
MCL1 Q07820 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
HSD17B10 Q99714 5/20 0.49
HPGD P15428 4/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
TSHR P16473 1/20 0.49
GFER P55789 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3564365 0.82 SLC6A4 (0.43) HTR6HTR1DHTR1AHTR7HTR5A
SCHEMBL3563207 0.82 HTR7 (0.60) HTR6HTR1DHTR1AHTR7HTR5A
SCHEMBL3563594 0.81 HTR6 (0.67) HTR6HTR1DHTR1AHTR7HTR5A
SCHEMBL3556246 0.79 HTR6 (0.56) HTR6HTR1DHTR1AHTR7HTR2A
SCHEMBL29633021 0.78 HTR6 (1.00) HTR6HTR1DHTR1AHTR7HTR5A
SCHEMBL5766124 0.78 HTR6 (1.00) HTR6HTR1DHTR1AHTR7HTR5A
SCHEMBL1793220 0.76 PARP1 (0.56) HTR6HTR1DHTR1AHTR7HTR5A
SCHEMBL11488806 0.76 HTR6 (0.76) HTR6HTR1DHTR1AHTR7HTR5A
SCHEMBL3563997 0.74 ADRA2A (0.50) HTR6HTR7KDM4EMAPTSLC6A4
SCHEMBL3563693 0.74 HTR6 (0.63) HTR6HTR1DHTR1AHTR7HTR5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567492-B1 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LTD (IN) 2013-05-22 EP disclosed
US-7718690-B2 N-arylsulfonyl-3-aminoalkoxyindoles RAMAKRISHNA VENKATA SATYA NIROGI 2010-05-18 US disclosed
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles SUVEN LIFE SCIENCES LIMITED (IN) 2009-05-21 US disclosed
EP-1567492-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES Suven Life Sciences Limited (IN) 2005-08-31 EP disclosed
WO-2004048328-A2 N-ARYLSULFONYL-3-AMINOALKOXYINDOLES SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO disclosed
WO-2004048331-A1 N-ARYLALKYL-3-AMINOALKOXYINDOLES AND THEIR USE AS 5-HT LIGANDS SUVEN LIFE SCIENCES LIMITED (IN) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131507-A1 N-arylsulfonyl-3-aminoalkoxyindoles HTR3C, HTR3A, AANAT HTR6 56/4885HTR1D 32/4885HTR1A 20/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.